Total no. of beneficiaries | 1 864 796 | 8 314 971 | +613 | 1 822 971 | −53 |
|
Total no. of prescriptions | 6 126 278 | 15 280 827 | +299 | 3 462 439 | −52 |
|
Rate of prescription use per 1000 people | 756 | 2,952 | +74 | 1421 | −52 |
|
Overall plan costs, $ | 378 864 749 | 838 556 189 | +254 | 203 827 168 | −49 |
|
Rate of cost per 1000 people, $ | 4602 | 16 202 | +252 | 1606 | −99 |
|
Drug prescriptions (asthma) | 408 517 | 1 617 430 | +534 | 307 354 | −59 |
|
Omalizumab | 28 | 2704 | +17 900 | 552 | −56 |
|
Mometasone | 51 | 1369 | +4450 | 46 | −92 |
|
Budesonide | 8632 | 47 245 | +775 | 11 194 | −49 |
|
Formoterol and mometasone | 3733 | 18 618 | +696 | 3513 | −60 |
|
Rate of use of asthma drugs per 1000 people | 52 | 309 | +494 | 126 | −59 |
|
Drug prescriptions (diabetes) | 69 598 | 172 492 | +297 | 36 471 | −55 |
|
Empagliflozin | 98 | 1596 | +2500 | 655 | −12 |
|
Insulin glulisine | 340 | 1818 | +764 | 318 | −63 |
|
Metformin and sitagliptin | 1270 | 2731 | +244 | 1106 | −13 |
|
Rate of use of diabetes drugs per 1000 people | 9 | 33 | +288 | 15 | −55 |
|
Drug plan expenditure (asthma), $ | 15 731 734 | 67 238 150 | +584 | 12 598 120 | −20 |
|
Omalizumab | 41 642 | 4 183 232 | +15 974 | 765 228 | −61 |
|
Ipratropium | 25 720 | 6827 | +9452 | 17 331 | −98 |
|
Mometasone | 2456 | 75 830 | +4856 | 2344 | −93 |
|
Rate of cost for asthma prescriptions per 1000 people | 1940 | 12 990 | +570 | 4548 | −64 |
|
Drug expenditure (diabetes), $ | 15 731 734 | 67 238 150 | +584 | 12 598 120 | −20 |
|
Empagliflozin | 8785 | 176 536 | +3100 | 56 926 | −31 |
|
Dapagliflozin | 3856 | 51 501 | +2032 | 5075 | −79 |
|
Insulin glulisine | 28 803 | 173 455 | +864 | 32 635 | −60 |
|
Rate of cost for diabetes prescriptions per 1000 people | 716 | 3584 | +410 | 1489 | −62 |